Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL407525 | 0.81 | USP2 (0.48) | ALDH1A1KDM4EPKMDNM1CA1 | |
| SCHEMBL25100142 | 0.80 | ALDH1A1 (0.38) | ALDH1A1KDM4EPKMDNM1CA1 | |
| SCHEMBL2876635 | 0.79 | KDM4E (0.42) | ALDH1A1KDM4EPKMDNM1CA1 | |
| SCHEMBL19116116 | 0.79 | USP2 (0.57) | ALDH1A1KDM4EPKMDNM1CA1 | |
| SCHEMBL19116285 | 0.79 | ALDH1A1 (0.41) | ALDH1A1TDP1USP2TSHRPAOX | |
| SCHEMBL26048799 | 0.79 | ALDH1A1 (0.41) | ALDH1A1TDP1USP2TSHRPAOX | |
| SCHEMBL19116169 | 0.79 | ALDH1A1 (0.41) | ALDH1A1TDP1USP2TSHRPAOX | |
| SCHEMBL2624391 | 0.78 | ALDH1A1 (0.46) | ALDH1A1KDM4EPKMDNM1CA1 | |
| SCHEMBL19115849 | 0.77 | ALDH1A1 (0.36) | ALDH1A1KDM4EPKMDNM1CA1 | |
| SCHEMBL19116205 | 0.77 | ALDH1A1 (0.36) | ALDH1A1KDM4EPKMDNM1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230302091-A1 | Combination Therapy with Controlled-Release CNP Agonists | ASCENDIS PHARMA GROWTH DISORDERS AS (DK) | 2023-09-28 | — | — | US | disclosed |
| EP-4162955-A1 | CNP PRODRUGS WITH CARRIER ATTACHMENT AT THE RING MOIETY | Ascendis Pharma Growth Disorders A/S (DK) | 2023-04-12 | — | — | EP | disclosed |
| WO-2018011266-A1 | CONJUGATION METHOD FOR CARRIER-LINKED PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2018-01-18 | — | — | WO | disclosed |
| WO-2017118693-A1 | CNP PRODRUGS WITH LARGE CARRIER MOIETIES | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2017-07-13 | — | — | WO | disclosed |
| WO-2017118698-A1 | CNP PRODRUGS WITH CARRIER ATTACHMENT AT THE RING MOIETY | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2017-07-13 | — | — | WO | disclosed |
| WO-2017118707-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH REDUCED SIDE-EFFECTS | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2017-07-13 | — | — | WO | disclosed |
| WO-2017118700-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH INCREASED NEP STABILITY | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2017-07-13 | — | — | WO | disclosed |
| WO-2017118704-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW NPR-C BINDING | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2017-07-13 | — | — | WO | disclosed |
| WO-2017118703-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW INITIAL NPR-B ACTIVITY | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2017-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230302091-A1 | Combination Therapy with Controlled-Release CNP Agonists | CNP, NPR1, NGF | ALDH1A1 3630/4885KDM4E 4731/4885PKM 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.